The fact that the analysis of data gained in the Eastern Cooperative Oncology Group adjuvant trial E1199 showed a strong negative effect of obesity on outcome in patients with hormone receptor-positive breast cancer that received a similar endocrine treatment as the patients in our study (i.e., either tamoxifen alone or tamoxifen followed by an aromatase inhibitor) [6] does not argue against such a possible masking effect of antihormone therapy, as the median follow-up time in the E1199 trial was 95 months and thus far exceeded the duration of anti-hormone therapy. This evidence concerns the gene CYP19A1 and obesity disorder.